ADMA Biologics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015; filed March 23, 2016. ADMA is a late-stage biopharmaceutical company developing plasma-derived biologics, primarily RI-002, and operating two FDA-licensed plasma collection centers in Georgia.
Business Context and Development Status
- RI-002, an RSV-antibody-enriched intravenous immune globulin intended for primary immune deficiency disease, completed a pivotal Phase III trial involving 59 patients and 793 infusions, with no serious bacterial infections or serious adverse events reported.
- The FDA accepted ADMA’s Biologics License Application for review on September 18, 2015, following submission on July 31, 2015.
- The company anticipated potential FDA approval and initial commercial sales during 2016, subject to regulatory review and manufacturing readiness.
- Revenue currently comes primarily from sales of normal source plasma; ADMA had not generated revenue from RI-002 therapeutics.
Financial Performance and Liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Total revenue | $7.18 million | $5.92 million | Up $1.26 million |
| Product revenue | $7.05 million | $5.84 million | Up $1.21 million |
| License and other revenue | $0.13 million | $0.08 million | Up $0.05 million |
| Cost of product revenue | $4.31 million | $3.74 million | Up $0.57 million |
| Gross profit | $2.87 million | $2.17 million | Up $0.69 million |
| Gross margin | 39.9% | 36.7% | Improved |
| Loss from operations | $(15.51) million | $(16.02) million | Improved $0.50 million |
| Net loss | $(17.97) million | $(16.81) million | Worsened $1.16 million |
| Basic and diluted loss per share | $(1.73) | $(1.81) | Improved |
| Cash used in operating activities | $(15.42) million | $(14.70) million | Higher use |
- Year-end cash and cash equivalents were $10.44 million, short-term investments were $6.37 million, and working capital was approximately $17.0 million.
- Inventories increased to $3.45 million from $1.71 million, primarily reflecting plasma accumulated for anticipated commercial manufacturing.
- Debt included $14.25 million of Oxford notes payable, net of discounts, plus a $1.43 million end-of-term liability. Total liabilities were $22.89 million versus $21.01 million at December 31, 2014.
- Stockholders’ equity declined to $0.82 million from $6.01 million, principally due to the annual net loss.
- Operating cash flow remained negative, and the company reported an accumulated deficit of $87.4 million.
Material Changes Versus 2014
- Revenue increased 21%, primarily because the Marietta plasma center began generating sales after receiving FDA approval to sell plasma in the United States in September 2015.
- Research and development expense declined 26% to $7.02 million as the Phase III trial and most drug-product manufacturing were completed in 2014. The reduction was partly offset by BLA-related regulatory consulting, testing, and validation costs.
- Plasma center expense increased 20% to $4.62 million due to the operation and ramp-up of the second collection facility.
- General and administrative expense increased 40% to $6.75 million, driven largely by pre-launch commercialization planning, market research, and related consulting.
- Interest expense increased to $1.84 million, and ADMA recorded a $0.72 million loss on extinguishment of debt following refinancing of its Hercules facility with Oxford.
- ADMA issued approximately 1.41 million common shares in March 2015 for net proceeds of approximately $10.2 million.
Outlook, Financing, and Key Risks
- Management stated that cash, short-term investments, and expected operating resources were sufficient to fund operations into the second half of 2016, but additional equity or debt financing would be required thereafter.
- The independent auditor included a going-concern explanatory paragraph, citing recurring losses, negative operating cash flow, and the need for additional capital.
- Oxford provided a $16.0 million term loan in June 2015; an additional $5.0 million may be available if RI-002 receives FDA approval by January 31, 2017. Principal repayment was scheduled to begin February 1, 2017, subject to possible interest-only extensions.
- RI-002 depends on FDA approval, satisfactory manufacturing inspections, continued third-party manufacturing capacity, adequate plasma supply, physician and payer acceptance, and reimbursement.
- Substantially all revenue and trade receivables were attributable to a single customer, Biotest, creating significant customer concentration risk.
- ADMA relies on third parties for key manufacturing, plasma supply, testing, and development activities. The contract manufacturer had received an FDA warning letter relating to another facility, although the filing stated that RI-002 production and delivery had not been affected.
- Additional risks include product liability, contamination or transmissible disease, plasma-center licensing, competition, intellectual-property challenges, stock dilution, debt acceleration, and potential inability to continue as a going concern.
Important Facts for Investors to Verify
- Current status and outcome of the RI-002 BLA review, including any FDA approval, complete response letter, labeling limitations, or post-approval requirements.
- Actual cash runway, subsequent financing transactions, dilution, and compliance with Oxford debt covenants and repayment terms.
- Whether RI-002 achieved commercial manufacturing scale-up and whether adequate high-titer RSV plasma and third-party manufacturing capacity are available.
- Customer concentration and the continuing terms of the Biotest plasma supply, manufacturing, licensing, and royalty arrangements.
- Post-2015 revenue mix, plasma-center utilization, gross margins, inventory realizability, and any plasma write-offs or product recalls.
- Reimbursement, pricing, market acceptance, and the timing of commercial launch if RI-002 was approved.